The price, which is confidential and was negotiated for a maximum of 300 zillion doses, is a little less than the $19.50 a picture the United States agreed to buy a very first shipment of 100 million doses of the identical vaccine, in line with what Reuters reported in November.
The EU document dated Nov. 18 was circulated internally after the EU announced the supply package of its with Pfizer and its German partner BioNTech on Nov. eleven.
The EU drug regulator is actually expected to determine on Monday on endorsement for the Pfizer vaccine after the photo was authorised in several countries, including Britain as well as the United States.
On Thursday Belgian state secretary with the spending budget Eva De Bleeker printed on Twitter a table with prices Belgium would pay pharmaceutical companies for the COVID 19 vaccines of theirs. She retracted the post shortly after posting.
In this dining room table the Pfizer vaccine was indicated as costing Belgium 12 euros ($14.6) per dose, leading many to believe that was the full price agreed with the EU.
Other vaccines in the family table were additionally shown with prices lower than rates disclosed by EU sources.
“There is for sure a total price along with a cost after delivery,” an EU official required in talks with vaccine makers told Reuters when directed to clarify the big difference between the EU and Belgian rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament previous week. In that public hearing, De Beeker said Belgium’s budgeted prices were still partial.
Under EU advanced purchase deals for COVID 19 vaccines, the bloc concurs initial payments with business enterprises to secure doses before they are approved. Following approvals, EU governments can pay the remainder to buy reserved doses.
The EU has not revealed the initial payment agreed with Pfizer.
But, it stated in October which it paid about 1 billion euros found in downpayments to AstraZeneca, Sanofi and Johnson and Johnson for their shots, with an additional 1.45 billion euros budgeted for upfront payments to Pfizer-BioNTech, Curevac and Moderna.
It’s since agreed source deals with all six companies and it is negotiating a seventh arrangement with Novavax.